Short answer
Spyre Therapeutics, Inc. (SYRE) filed an 8-K current report with the SEC on May 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q1 2026 financial results for quarter ended March 31, 2026.
Spyre Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q1 2026 financial results for quarter ended March 31, 2026
- Press release furnished as Exhibit 99.1 with detailed results
- May 5, 2026 disclosure provides investors access to quarterly financial performance
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Spyre Therapeutics, Inc. 8-K filings
Get the next SYRE 8-K as it lands
Follow SYRE for push alerts, or ask the research agent what this filing means.